medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

1999, Number 5

<< Back

Alerg Asma Inmunol Pediatr 1999; 8 (5)

Inhaled steroids. Pharmacology and clinical applications

Hernández VT

Language: Spanish
References: 39
Page: 139-147
PDF size: 422.57 Kb.


ABSTRACT

Corticosteroids are potent anti-inflammatory drugs that have been used in the treatment of respiratory diseases since 1950. The exact mechanisms of action in pulmonary diseases are still not well defined corticosteroids in vitro induce the production of lipocortin 1, which facilites inhibition of the synthesis of phospholipase A2, the rate-limiting enzyme in the mobilization of arachidonic acid from membrane phospholipids. As a consequence, the production of many mediators, such as prostaglandins, thromboxane, and leukotrienes is reduced. The rationale for using the inhaled route is that medication is delivered directly to the airways, allowing for a rapid onset of action, lower, dosage requirements, and fewer systemic side effects compared with oral therapy. At the present time, three inhalation systems are available for delivery of steroids: meter dose inhalers, dry powder inhalers and nebulizer. There are many respiratory diseases in which corticosteroids may be useful: asthma, croup, bronchiolitis, cystic fibrosis, etc.


REFERENCES

  1. Barnes PJ, Adocock IM. Anti-inflammatory actions of steroids: molecular mechanism. Trends Pharmacol Sci 1993; 14: 436-41.

  2. Högger P, Rawert L, Rohdewald P. Dissolution tissue binding and kinetics of receptor binding of inhaled glucocorticoids (abstract). Eur Resp J 1993; 6: 584S.

  3. Högger P, Bonsmann U, Rohdewald P. Efflux of glucocorticoids from human lung tissue to human plasma in vitro. Eur Respir J 1994; 7: 382S.

  4. Van den Bosch JMM, Westermann CJJ, Aumann J et al. Relation ship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharm Drug Dispos 1993; 14: 455-9.

  5. Högger P, Esmailpour N, Rabe K et al. Distribution of inhaled fluticasone propionate between lung tissue and blood plasma in vivo. Eur Respir J 1995; 8: 3035.

  6. Högger P, Rohddewal P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 1994; 59: 597-602.

  7. English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994; 149: A212.

  8. Derendof H, Hochtraus G, Möllmann H et al. Receptor-based pharmacokineticpharmacodynamic analysis of corticosteroids. J Clin Pharmacol 1993; 33: 115-23.

  9. Brasttsand R, Selroos O. Current drugs for respiratory diseases. In: Page CP, Metzger WJ (Ed). Drugs and the lung. Raven Press, New York 1994: 101-220.

  10. Edsbäcker S, Andersson KE, Ryrfeld A. Nasal bioavailability and systemic effects of the glucocorticoid budesonide in man. Eur J Clin Pharmacol 1995; 29: 477-81.

  11. Mc Dowall JE, Mackie AE, Bye A, Ventresia GP. Very low systemic exposure to intranasal fluticasone propionate (abstract). J Allergy Clin Immunol 1995; 95: 194.

  12. Rohdewald P, Reheder S. Plasma levels of beclomethasone dipropionate (BDP) and its 17-monopropionate metabolite (17-MDP) and following BDP inhalation (Abstract). Eur Respir J 1994; 7: 3825.

  13. Toogood JH, Lefcoe MN, Haines DSM et al. A graded dose assessment of the efficacy of beclomethasone dipropionate aerosol for severe chronic asthma. J Allergy Clin Immunol 1997; 59: 248-308.

  14. Smith MJ, Hodson ME. High dose beclomethasone inhaler in the treatment of asthma. Lancet 1983; 1: 265-9.

  15. Dahl R, Lundback B, Malo J et al. A dose ranging study of fluticasone propionate in adults with moderate asthma. Chest 1993; 104: 1352-8.

  16. Ayres JG, Bateman ED, Lunback B et al. High dose fluticasone propionate 2 mg daily or budesonide, 1.6 mg daily in patients with chronic severe asthma. Eur Respir J 1995; 8: 579-86.

  17. Laitinen LA, Laitinen A, Haathela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and of a B2 agonist, terbutaline on airway inflammation in newly diagnosed asthma: A randomized, double-blind paraller-group controlled trial. J Allergy Clin Immunol 1992; 90: 32-42.

  18. Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holtgate ST. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 1992; 145: 669-74.

  19. Burke C, Power CK, Norris A, Condez A, Schmekel B, Poulter LW. Lung function and immunopathological changes after inhaled corticosteroid therapy in asthma. Eur Respir J 1992; 5:73-79.

  20. Kraan J, Koeter GH, Vander Mark TW, Boorsma M, Kukler J, Sluiter HJ, de Uriesk. Dosage and time effect of inhaled budesonide on bronchial hyperreactivity. Am Rev Respir Dis 1988; 137: 44-48.

  21. Juniper EF, Line PA, Vanzieleghem MA, Ramsdale EH, O’Byrne PM, Hargreave FE. Effect of long-term treatment with an inhaled corticosteroid (Budesonide) on airway hiperresponsiveness a clinical asthma in non steroid-dependent asthmatics. Am Rev Respir Dis 1990; 142: 832-836.

  22. Bel EH, Timmers MC, Zwinderman AH, Dijkman JH, Sterk PJ. The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. Am Rev Respir Dis 1991; 143: 109-113.

  23. Vathebnen AS, Knox AJ, Wisniewski A, Tattersfield AE. Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 1991; 143: 1317-1321.

  24. Waalkens HJ, van Essen-Zandvliet EE, Hughes MD, Gerritsen J, Duiverman EJ, Knol K, Kerrebijn KF, Dutch. Chronic Non-Specific Lung Disease Study Group. Cessation of long-term treatment with inhaled corticosteroids (budesonide) in children with asthma results in deterioration. Am Rev Respir Dis 1993; 148: 1252-1257.

  25. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Selroos O, Sovijärvi A, Stenius-Aarniala R, Svahn T, Tammivaara R, Laitinen LA. Effects of reducing or discontinuating inhaled budesonide in patients with mild asthma. N Engl J Meds 1994; 331: 700-705.

  26. Agertofort L, Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary functions in asthmatic children. Respir Med 1994; 88: 373381.

  27. Jones AH, Langdon CG, Lee PS, Linghain SA, Nankani JP, Follows RM, Tollemar U, Richardson PD. Pulmicort Turbuhaler once daily as initial prophylactic therapy for asthma. Respir Med 1994; 88: 293-299

  28. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma: A dose-response study. J Allergy Clin Immunol 1995; 95:29-33.

  29. Scarfore R, Fuchs S, Nager A, Shane SA. Controlled trial of oral prednisone in the emergency department treatment of children with acute asthma. Pediatrics 1993; 92: 513-518.

  30. Horowitz L, Zafrir O, Gilboa S, Berger I, Wolach B. Acute asthma. Single dose oral steroids in paediatric community clinics. Eur J Pediatr 1994; 153: 526-530.

  31. Greos LS, Vichyanon P, Bloedow DC, Irvin CG, Larsen GL, Szefler SJ, Hill MR. Methylprednisolone achieves greater concentrations in the lung than prednisolone. Am Rev Respir Dis 1991; 144: 586-592.

  32. Skolnik NS. Treatment of Croup. A critical review. Am J Dis Child 1989; 143: 10451049.

  33. Kairys SW, Olmstead EM, O’Connor GT. Steroid treatment of laryngotracheobronchitis: A meta-analysis of the evidence from randomized trials. Pediatrics 1989; 83: 683-693.

  34. Geelhoed GC, Macdonald WBG. Oral dexamethasone in the treatment of Croup: 0.15 mg/kg versus 0.6 mg/kg. Pediatr Pulmonol 1995; 20: 362-368.

  35. Landau LI, Geelhoed GC. Aerosolized steroids for Croup. N Engl J Med 1994; 331: 322-323.

  36. Panitch HB, Callhan CW Jr, Schidlow DV. Bronchiolitis in children. Clin Chest Med 1993; 14: 715-731.

  37. Auerbanch HS, Williams M, Kirkpatrick JA, Colten HR. Alternate day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet 1985; 2: 686-688.

  38. Eigen H, Rosenstein B, Fitz Simmons S, Schidlow DV. The Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995; 126: 515-523.

  39. Inhaled corticosteroids-first-line preventive therapy in asthma: evidence from the current medical literature (supplement). J Allergy Clin Immunol 1998; 102(4) Pt2 S52-S63.




2020     |     www.medigraphic.com